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Abstract: Introduction: Citrullination as well as anti-citrullinated protein/peptide antibodies (ACPA) 
have been implicated in the pathogenesis of rheumatoid arthritis (RA). While ACPAs are specific and 
sensitive markers for RA, there have been hardly any reports regarding ACPAs in ankylosing 
spondylitis (AS). The possible role of antibodies to Mycobacterial 65 kDa heat shock protein (hsp65) 
has not been characterized in AS. As new laboratory biomarkers of AS are needed, we investigated the 
prevalence of anti-mutated citrullinated vimentin (MCV) and anti-hsp65 antibodies in AS. 
Methods: Altogether 43 AS and 44 healthy controls were included in the study. Anti-MCV and anti-
hsp65 were determined in sera by commercial and in-house ELISA, respectively. Serum autoantibody 
levels were correlated with ESR, CRP, HLA-B27 status, smoking habits, pain intensity, BASDAI, BASFI 
and BASMI indices. 
Results: Patients with AS had significantly higher serum anti-MCV levels (17.3 U/ml, range: 8.3-31.5 
U/ml) in comparison to healthy subjects (8.9 U/ml, range: 5.4-13.3 U/ml) (p<0.01). Sixteen of the 43 
AS patients (37%) and none of the 44 healthy controls (0%) were anti-MCV positive using the cut-off 
value recommended by the manufacturer (> 20 U/ml). The mean anti-hsp65 concentration in AS sera 
was 124.8 AU/ml (range: 27.2-1000 AU/ml), while controls exerted significantly lower anti-hsp65 
levels (mean: 51.8 AU/ml; range: 22.5-88.5 AU/ml) (p<0.001). Correlation analysis revealed that both 
anti-MCV positivity (r=0.613; p=0.012) and absolute serum anti-MCV levels (r=0,553; p=0.021) 
correlated with anti-hsp65 levels. Anti-MCV positivity also correlated with ESR (r= 0.437; p=0.03). 
Conclusions: Anti-MCV and anti-hsp65 may be novel biomarkers in AS.   
 
 
 
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 1 
 
 
Anti-mutated citrullinated vimentin (anti-MCV) and anti-65 kDa heat 
shock protein (anti-hsp65): new biomarkers in ankylosing spondylitis 
 
Nóra Bodnár
1
, Zoltán Szekanecz
1
, Zoltán Prohászka
5
, Ádám Kemény-Beke
2
,  
Zsuzsanna Némethné-Gyurcsik
3
, Katalin Gulyás
1
, Gabriella Lakos
4,6
, Sándor Sipka
4
, Sándor 
Szántó
1 
 
 
1
Department of Rheumatology, Institute of Medicine; 
2
Department of Ophthalmology, 
3
Department of Physiotherapy and 
4
Laboratory of Immunology, Third Department of 
Medicine, Institute of Medicine, University of Debrecen Medical and Health Science Center, 
Debrecen, Hungary; 
5
Third Department of Internal Medicine, Faculty of Medicine, Semmelweis University, 
Budapest, Hungary; 
6
TheraTest Laboratories Inc., Lombard, IL, USA   
 
Running head: Anti-MCV and anti-hsp65 in ankylosing spondylitis 
Key words: ankylosing spondylitis, ACPA, anti-MCV, anti-hsp65 
 
 
Corresponding author: Prof. Dr. Zoltán Szekanecz, MD, PhD. Department of 
Rheumatology, Institute of Medicine, University of Debrecen Medical and Health Science 
Center, 98 Nagyerdei str, Debrecen, H-4012, Hungary.  
Phone/fax: +36-52-255-091; fax: +36-52-414-489; e-mail: szekanecz.zoltan@med.unideb.hu 
Website : www.rheumatology.hu 
Manuscript
Click here to download Manuscript: Bodnr-spa-mcvhsp-JBS-2011-corrected.doc
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 2 
List of abbreviations 
 
ACPA  anti-citrullinated protein antibodies 
AS  ankylosing spondylitis 
BASDAI Bath ankylosing spondylitis disease activity index 
BASFI  Bath ankylosing spondylitis functional index 
BASMI Bath ankylosing spondylitis metric index 
CCP  cyclic citrullinated peptide 
CF  citrullinated fibrinogen 
CRP  C reactive protein 
CV  citrullinated vimentin 
DMARD disease-modifying antirheumatic drug 
ELISA  enzyme-linked immunosorbent assay  
ESR  erythrocyte sedimentation rate 
HLA  human leukocyte antigen 
Hsp  heat shock protein 
IgG  immunoglobulin G 
MCV  mutated citrullinated vimentin 
MRI  magnetic resonance imaging 
NSAID nonsteroidal antiinflammatory drug 
PsA  psoriatic arthritis 
RA  rheumatoid arthritis 
Sa  Savoie 
SpA  spondylarthritis (spondylarthropathy) 
TNF  tumor necrosis factor 
VAS  visual analogue scale 
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Abstract 
 
Introduction: Citrullination as well as anti-citrullinated protein/peptide antibodies (ACPA) 
have been implicated in the pathogenesis of rheumatoid arthritis (RA). While ACPAs are 
specific and sensitive markers for RA, there have been hardly any reports regarding ACPAs 
in ankylosing spondylitis (AS). The possible role of antibodies to Mycobacterial 65 kDa heat 
shock protein (hsp65) has not been characterized in AS. As new laboratory biomarkers of AS 
are needed, we investigated the prevalence of anti-mutated citrullinated vimentin (MCV) and 
anti-hsp65 antibodies in AS. 
Methods: Altogether 43 AS and 44 healthy controls were included in the study. Anti-MCV 
and anti-hsp65 were determined in sera by commercial and in-house ELISA, respectively. 
Serum autoantibody levels were correlated with ESR, CRP, HLA-B27 status, smoking habits, 
pain intensity, BASDAI, BASFI and BASMI indices. 
Results: Patients with AS had significantly higher serum anti-MCV levels (17.3 U/ml, range: 
8.3-31.5 U/ml) in comparison to healthy subjects (8.9 U/ml, range: 5.4-13.3 U/ml) (p<0.01). 
Sixteen of the 43 AS patients (37%) and none of the 44 healthy controls (0%) were anti-MCV 
positive using the cut-off value recommended by the manufacturer (> 20 U/ml). The mean 
anti-hsp65 concentration in AS sera was 124.8 AU/ml (range: 27.2-1000 AU/ml), while 
controls exerted significantly lower anti-hsp65 levels (mean: 51.8 AU/ml; range: 22.5-88.5 
AU/ml) (p<0.001). Correlation analysis revealed that both anti-MCV positivity (r=0.613; 
p=0.012) and absolute serum anti-MCV levels (r=0,553; p=0.021) correlated with anti-hsp65 
levels. Anti-MCV positivity also correlated with ESR (r= 0.437; p=0.03). 
Conclusions: Anti-MCV and anti-hsp65 may be novel biomarkers in AS.   
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Introduction 
 
Ankylosing spondylitis (AS) is an inflammatory rheumatic disease that may lead to 
functional impairment of the spine and peripheral joints. Genetic predisposition and 
environmental factors have been implicated in the pathogenesis of AS [1, 2]. With new and 
very effective therapeutic approaches, such as biologics becoming available, it is imperative 
to recognize and treat AS as early as possible in order to prevent disability. In early stages, 
spinal and sacroiliac MRI may be a useful radiological tool for the diagnosis and follow-up of 
AS [3, 4], however, there is a need for laboratory biomarkers. While anti-citrullinated 
protein/peptide antibodies (ACPA) have become rather specific and sensitive diagnostic tools 
in rheumatoid arthritis (RA) [5-10], such autoantibodies have not yet been identified in AS. 
ACPAs including anti-cyclic citrullinated peptide (CCP), anti-citrullinated vimentin 
(CF), anti-citrullinated fibrinogen (CF), anti-citrullinated α enolase and some others have 
been implicated in the pathogenesis and outcome of RA [6-8, 11-19]. ACPA production has 
been associated with interactions of HLA-DRB1 alleles and lifestyle-related factors, such as 
smoking in RA, as well as more destructive joint damage [8, 11, 19-21].  
The anti-Savoie (Sa) antibody was long ago described as specific diagnostic and 
prognostic marker in RA. It has later been demonstrated that anti-Sa specifically recognizes 
CV [22]. In order to detect antibodies to CV, an ELISA system was developed that contains 
genetically modified, mutated citrullinated vimentin (MCV) as autoantigen to improve the 
performance of the test.  We and others have shown that anti-MCV ELISA is a very sensitive 
and specific diagnostic tool in RA. It has also been associated with HLA-DRB1 and 
radiological progression [7, 11, 18, 23-26].  
There have been few data on the possible associations of ACPA with 
spondyloarthropathies (SpA), such as AS. In AS, some HLA-B27 allele variants, specifically 
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HLA-B*2705 and B*2709 may undergo citrullination, which alters their capacity of antigen 
presentation [27]. In a recent study, 15% of PsA and 14% of AS patients were positive for 
anti-MCV [28].  
Autoantibodies to heat shock proteins (hsp) have been implicated in inflammation, 
autoimmunity and atherosclerosis. Among inflammatory rheumatic diseases, anti-hsp65 
antibodies were detected in the sera of RA patients [29-31]. Regarding AS, Mycobacteria 
have been implicated in the pathogenesis of the disease [32, 33], however, there have been no 
reports on anti-hsp65 in relation with other clinical and laboratory markers. In one early 
study, serum anti-hsp65 was measured in AS, RA patients and controls. Although anti-hsp65 
was elevated in 19/59 patients (32%), the level of elevation was not significant. In contrast, 
significantly elevated IgA anti-hsp65 was observed in RA [34]. No other reports on anti-
hsp65 in relation to AS have become available.  
Thus, there have been no studies assessing anti-MCV and anti- Mycobacterial hsp65 
production in AS in association with other clinical and laboratory parameters. Based on data 
on the possible role of citrullination and Mycobacterial infection in AS, as well as RA, our 
hypothesis was that antibodies to citrullinated proteins and hsp may be associated with AS. 
Therefore, in the present study, we assessed anti-MCV and anti-hsp65 levels in the sera of AS 
patients and healthy controls. In AS, we correlated anti-MCV and anti-hsp65 with each other, 
as well as with disease duration, erythrocyte sedimentation rate (ESR), C reactive protein 
(CRP), HLA-B27 status, BASDAI, BASFI, BASMI, and pain on visual analogue scale 
(VAS). As ACPA production has been associated with smoking in RA [21], we also 
correlated antibody production with the smoking habits of AS patients. 
 
Patients and methods 
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Patients and controls 
 
Altogether 43 AS patients (31 males – 72% and 12 females - 28%; mean age: 45.4 ± 
11.8 years, range: 26-75 years; all Caucasians) were included in the study. The diagnosis of 
AS was based on the modified New York criteria [35]. Among the 43 patients, 33 (76.7%) 
had only axial involvement, while 10 (23.3%) also had peripheral arthritis. Other information 
on the AS group is included in Table 1. Altogether 36 patients (83.7%) were HLA-B27 
positive. Fourteen out of the 43 AS patients (32.6%) were in active state of disease (BASDAI 
>40). Most patients (37/43, 86%) received nonsteroidal antiiflammatory drugs (NSAID). 
Among the 10 AS patients with peripheral involvement, 6 (60%) received conventional 
DMARDs including methotrexate or sulfasalazine. Altogether 28 patients (65.1%) currently 
received anti-TNF biologics. None of the AS patients were genetically related or had any type 
of arthritis in their family.  
Regarding clinical assessments, AS disease activity, functional capacity and mobility 
were tested by obtaining BASDAI, BASFI and BASMI, respectively. Pain intensity was 
recorded on a VAS scale. ESR (mm/h) was assessed by the Westergren method. Serum CRP 
levels (mg/l) were measured by quantitative turbidimetry (Cobas Mira Plus, Roche), using 
CRP reagents (Dialab, Austria). HLA-B27 genotyping was performed by using polymerase 
chain reaction-sequence specific primer (PCR-SSP) technique (HISTO TYPE B27 High 
resolution kit, BAG, Lich, Germany).  
For comparisons, we also tested 44 healthy volunteers (28 males – 64% and 16 
females - 36%; mean age: 42.7 ± 9.2 years) for anti-MCV and 11 patients with low back pain 
but no AS (7 males – 64% and 4 females – 36%; mean age: 46.3 ± 11.4 years) for anti-hsp65. 
All AS patients and controls had a negative history for previous cardiovascular, 
cerebrovascular or peripheral arterial disease. Thirteen out of the 43 AS patients (30.2%) and 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 7 
15 out of 44 controls (34.0%) were current smokers. Regarding current tobacco smoking, we 
applied the cut-off points published by Pedersen et al [36] in RA (≥ 20 pack-years). 
Cumulative tobacco intake was calculated by multiplying the mean daily intake by the 
duration of consumption in years.  
Informed consent was obtained from each AS patient and healthy control subject 
according to the Declaration of Helsinki. For this study we also obtained local ethical 
committee approval at the University of Debrecen. Serum samples were then obtained from 
all subjects and kept frozen at -70
o
C until further use. 
 
Determination of anti-MCV and anti-hsp65 antibody levels  
 
 Anti-MCV IgG antibodies were assessed by ELISA (OrgenTec Diagnostika GmbH, 
Mainz, Germany) as described previously [7]. This assay contains recombinant MCV as 
antigen. The test was performed according to the manufacturer's instructions. The cut-off 
value for anti-MCV antibodies was 20 U/ml.  
 Amounts of IgG antibodies reacting with recombinant M. bovis hsp65 (Lionex, 
Braunschweig, Germany) were assessed by ELISA as described previously [37]. Data 
obtained as optical density values were calculated as arbitrary unit per ml (AU/ml) values 
related to standard.  
 
Statistical analysis 
 
 Antibody levels between different groups were compared by the non-parametric Mann 
Whitney U test. Spearman’s rank correlation was used to assess the relationship between anti-
MCV, anti-hsp65 levels and other parameters described above. P values < 0.05 were 
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considered significant. All statistical analyses were performed using the SPSS for Windows 
11.0 statistical package. 
 
Results 
 
Anti-MCV positivity and absolute levels in the study population 
 
 Patients with AS had significantly median higher serum anti-MCV levels (17.3 U/ml,  
range: 8.3-31.5 U/ml) in comparison to healthy subjects (8.9 U/ml, range: 5.4-13.3 U/ml) 
(p<0.01) (Figure 1).  
 Regarding anti-MCV positivity, 16 of the 43 AS patients (37%) and none of the 44 
healthy controls (0%) were anti-MCV positive using the cut-off value recommended by the 
manufacturer (> 20 U/ml). 
 Patients with axial versus peripheral AS, those with versus without psoriasis, uveitis or 
inflammatory bowel disease (IBD) did not differ in anti-MCV levels (data not shown).    
 
Anti-hsp65 levels in AS and controls 
  
 The median anti-hsp65 concentration in the sera of AS patients was 124.8 AU/ml 
(range: 27.2-1000 AU/ml), while the non-AS low back pain controls exerted significantly 
lower anti-hsp65 levels (median: 51.8 AU/ml; range: 22.5-88.5 AU/ml) (p<0.001) (Figure 2). 
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 Again, patients with axial versus peripheral AS, those with versus without psoriasis, 
uveitis or IBD did not differ in anti-hsp65 levels (data not shown).    
 
 
Relationship between anti-MCV, anti-hsp65 antibody levels and other parameters 
  
Interestingly, both anti-MCV positivity (r=0.613; p=0.012) and absolute serum anti-
MCV levels (r=0,553; p=0.021) exerted significant postive correlations with anti-hsp65 
levels. Anti-MCV positivity also correlated with ESR (r= 0.437; p=0.03).   
Neither anti-MCV, nor anti-hsp65 correlated with age, disease duration, CRP, HLA-
B27 status, smoking habits, pain intensity (VAS), BASDAI, BASFI or BASMI (data not 
shown). 
  
Discussion 
 
 ACPAs are considered to be specific and sensitive diagnostic markers of RA [5-7, 38]. 
While numerous autoantibodies of pathogenic, diagnostic and prognostic significance are 
available in other autoimmune-inflammatory diseases, AS has not yet been associated with 
such antibodies. Anti-MCV antibody production has been investigated in very few SpA 
studies. In one recent study, Damjanovska et al [28] compared anti-MCV production in 917 
patients with recent onset arthritis. This population included early RA, AS and PsA patients. 
The anti-MCV test had a higher sensitivity than two anti-CCP tests. In addition, while >80% 
of early RA patients were anti-MCV positive, only 15% of PsA and 14% of AS patients 
exerted anti-MCV seropositivity. In our present study, 37% of AS patients but only 4.5% of 
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healthy controls were anti-MCV positive. Moreover, AS patients had significantly higher 
serum anti-MCV levels than controls. Anti-MCV positivity in AS also correlated with acute 
phase protein production indicated by ESR. In contrast, anti-MCV did not correlate with 
HLA-B27 status, disease activity, functional and metric indices or smoking habits among AS 
patients. 
 Heat shock proteins, as well as antibodies against the Mycobacterial hsp65 have been 
implicated in the pathogenesis of vascular and autoimmune diseases [30, 33, 34]. There has 
been only one study reporting non-significant elevation of anti-hsp65 in 19 out of 59 AS 
patients [34], however anti-hsp65 was not assessed in association with other clinical or 
laboratory parameters. Here we also found significantly elevated serum anti-hsp65 levels in 
AS. Our results are somewhat different from those published by McLean et al [34] as in their 
study, the elevation of anti-hsp65 in AS compared to controls was not statistically significant.  
Interestingly, we also correlated anti-hsp65 and anti-MCV levels for the first time in 
the literature. There have been no reports on direct links between ACPA and anti-hsp 
autoantibody production in AS. As described above, Mycobacteria, and thus Mycobacterial 
hsp65 have been implicated in the pathogenesis of AS [32, 33]. Among citrullinated proteins, 
citrullinated vimentin has also been detected in the synovial tissues of SpA, as well as RA 
patients [39]. Thus, according to the molecular mimicry theory, AS induced by infectious 
agents including Mycobacteria may trigger synovial inflammation and synovitis in AS may 
also be associated with increased citrullination of synovial proteins [32, 33, 39]. It is not clear 
whether there would be a direct cross-reactivity between anti-MCV and anti-hsp65 antibodies 
in AS. 
 
Conclusion 
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 In conclusion, although the exact role of anti-MCV and anti- Mycobacterial hsp65 
autoantibodies in AS remains to be further characterized, our results suggest a possible novel 
role of these autoantibodies in AS. Moreover, as anti-hsp65 and anti-MCV exerted positive 
correlation with each other, these two, very different antibodies may have a role in the 
pathogenesis of AS and they may also serve as useful antibody biomarkers.  
 
 
Acknowledgements 
 
 This work was supported by supported by research grants T 048541 from the National 
Scientific Research Fund (OTKA) (Z.S.), 315/09 from the Medical Research Council (ETT) 
(Z.S.) and Mec-14/2005 grant from Debrecen University (S.S.) 
 
Figure legends 
 
Figure 1. Scatter plot showing anti-MCV levels in the sera of AS patients and controls. 
Figure 2. Scatter plot showing anti-hsp65 levels in the sera of AS patients and controls. 
 
 
 
 
 
References 
1. Salvarani C, Fries W: Clinical features and epidemiology of spondyloarthritides 
associated with inflammatory bowel disease. World J Gastroenterol 2009, 
15(20):2449-2455. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 12 
2. Vegvari A, Szabo Z, Szanto S, Glant TT, Mikecz K, Szekanecz Z: The genetic 
background of ankylosing spondylitis. Joint Bone Spine 2009, 76(6):623-628. 
3. Rudwaleit M, Landewe R, van der Heijde D, Listing J, Brandt J, Braun J, Burgos-
Vargas R, Collantes-Estevez E, Davis J, Dijkmans B et al: The development of 
Assessment of SpondyloArthritis international Society classification criteria for 
axial spondyloarthritis (part I): classification of paper patients by expert opinion 
including uncertainty appraisal. Ann Rheum Dis 2009, 68(6):770-776. 
4. Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J: MRI in 
predicting a major clinical response to anti-tumour necrosis factor treatment in 
ankylosing spondylitis. Ann Rheum Dis 2008, 67(9):1276-1281. 
5. Holers VM: Antibodies to citrullinated proteins: pathogenic and diagnostic 
significance. Curr Rheumatol Rep 2007, 9(5):396-400. 
6. Szekanecz Z, Soos L, Szabo Z, Fekete A, Kapitany A, Vegvari A, Sipka S, Szucs G, 
Szanto S, Lakos G: Anti-Citrullinated Protein Antibodies in Rheumatoid 
Arthritis: As Good as it Gets? Clin Rev Allergy Immunol 2008, 34(1):26-31. 
7. Soos L, Szekanecz Z, Szabo Z, Fekete A, Zeher M, Horvath IF, Danko K, Kapitany A, 
Vegvari A, Sipka S et al: Clinical evaluation of anti-mutated citrullinated vimentin 
by ELISA in rheumatoid arthritis. J Rheumatol 2007, 34(8):1658-1663. 
8. Klareskog L, Widhe M, Hermansson M, Ronnelid J: Antibodies to citrullinated 
proteins in arthritis: pathology and promise. Curr Opin Rheumatol 2008, 
20(3):300-305. 
9. Migliorini P, Pratesi F, Tommasi C, Anzilotti C: The immune response to 
citrullinated antigens in autoimmune diseases. Autoimmun Rev 2005, 4(8):561-564. 
10. Sebbag M, Chapuy-Regaud S, Auger I, Petit-Texeira E, Clavel C, Nogueira L, 
Vincent C, Cornelis F, Roudier J, Serre G: Clinical and pathophysiological 
significance of the autoimmune response to citrullinated proteins in rheumatoid 
arthritis. Joint Bone Spine 2004, 71(6):493-502. 
11. Gyetvai A, Szekanecz Z, Soos L, Szabo Z, Fekete A, Kapitany A, Teodorescu M, 
Sipka S, Szegedi G, Lakos G: New classification of the shared epitope in 
rheumatoid arthritis: impact on the production of various anti-citrullinated 
protein antibodies. Rheumatology (Oxford), 49(1):25-33. 
12. Ding B, Padyukov L, Lundstrom E, Seielstad M, Plenge RM, Oksenberg JR, 
Gregersen PK, Alfredsson L, Klareskog L: Different patterns of associations with 
anti-citrullinated protein antibody-positive and anti-citrullinated protein 
antibody-negative rheumatoid arthritis in the extended major histocompatibility 
complex region. Arthritis Rheum 2009, 60(1):30-38. 
13. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld 
FC, van Venrooij WJ: The diagnostic properties of rheumatoid arthritis antibodies 
recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000, 43(1):155-163. 
14. Kinloch A, Tatzer V, Wait R, Peston D, Lundberg K, Donatien P, Moyes D, Taylor 
PC, Venables PJ: Identification of citrullinated alpha-enolase as a candidate 
autoantigen in rheumatoid arthritis. Arthritis Res Ther 2005, 7(6):R1421-1429. 
15. Snir O, Widhe M, von Spee C, Lindberg J, Padyukov L, Lundberg K, Engstrom A, 
Venables PJ, Lundeberg J, Holmdahl R et al: Multiple antibody reactivities to 
citrullinated antigens in sera from patients with rheumatoid arthritis: association 
with HLA-DRB1 alleles. Ann Rheum Dis 2009, 68(5):736-743. 
16. Nielen MM, van der Horst AR, van Schaardenburg D, van der Horst-Bruinsma IE, van 
de Stadt RJ, Aarden L, Dijkmans BA, Hamann D: Antibodies to citrullinated human 
fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann 
Rheum Dis 2005, 64(8):1199-1204. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 13 
17. Dejaco C, Duftner C, Klotz W, Schirmer M, Herold M: Antibodies against mutated 
citrullinated vimentin fail to predict anti-TNFalpha treatment response in 
rheumatoid arthritis. Scand J Rheumatol 2009, 38(1):66-67. 
18. Innala L, Kokkonen H, Eriksson C, Jidell E, Berglin E, Dahlqvst SR: Antibodies 
against mutated citrullinated vimentin are a better predictor of disease activity at 
24 months in early rheumatoid arthritis than antibodies against cyclic 
citrullinated peptides. J Rheumatol 2008, 35(6):1002-1008. 
19. Szodoray P, Szabo Z, Kapitany A, Gyetvai A, Lakos G, Szanto S, Szucs G, Szekanecz 
Z: Anti-citrullinated protein/peptide autoantibodies in association with genetic 
and environmental factors as indicators of disease outcome in rheumatoid 
arthritis. Autoimmun Rev 2009. 
20. van der Helm-van Mil AH, Wesoly JZ, Huizinga TW: Understanding the genetic 
contribution to rheumatoid arthritis. Curr Opin Rheumatol 2005, 17(3):299-304. 
21. Klareskog L, Padyukov L, Lorentzen J, Alfredsson L: Mechanisms of disease: 
Genetic susceptibility and environmental triggers in the development of 
rheumatoid arthritis. Nat Clin Pract Rheumatol 2006, 2(8):425-433. 
22. Vossenaar ER, Despres N, Lapointe E, van der Heijden A, Lora M, Senshu T, van 
Venrooij WJ, Menard HA: Rheumatoid arthritis specific anti-Sa antibodies target 
citrullinated vimentin. Arthritis Res Ther 2004, 6(2):R142-150. 
23. Coenen D, Verschueren P, Westhovens R, Bossuyt X: Technical and diagnostic 
performance of 6 assays for the measurement of citrullinated protein/peptide 
antibodies in the diagnosis of rheumatoid arthritis. Clin Chem 2007, 53(3):498-
504. 
24. Dejaco C, Klotz W, Larcher H, Duftner C, Schirmer M, Herold M: Diagnostic value 
of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. 
Arthritis Res Ther 2006, 8(4):R119. 
25. Mathsson L, Mullazehi M, Wick MC, Sjoberg O, van Vollenhoven R, Klareskog L, 
Ronnelid J: Antibodies against citrullinated vimentin in rheumatoid arthritis: 
higher sensitivity and extended prognostic value concerning future radiographic 
progression as compared with antibodies against cyclic citrullinated peptides. 
Arthritis Rheum 2008, 58(1):36-45. 
26. Poulsom H, Charles PJ: Antibodies to Citrullinated Vimentin are a Specific and 
Sensitive Marker for the Diagnosis of Rheumatoid Arthritis. Clin Rev Allergy 
Immunol 2008, 34(1):4-10. 
27. Beltrami A, Rossmann M, Fiorillo MT, Paladini F, Sorrentino R, Saenger W, Kumar 
P, Ziegler A, Uchanska-Ziegler B: Citrullination-dependent differential 
presentation of a self-peptide by HLA-B27 subtypes. J Biol Chem 2008, 
283(40):27189-27199. 
28. Damjanovska L, Thabet MM, Levarht EW, Stoeken-Rijsbergen G, van der Voort EI, 
Toes RE, Huizinga TW, van der Helm-van Mil AH: The diagnostic value of anti-
MCV antibodies in differentiating early inflammatory arthritis. Ann Rheum Dis 
2009. 
29. van Halm VP, Slot MC, Nurmohamed MT, Cohen Tervaert JW, Dijkmans BA, 
Voskuyl AE: Antibodies against human 60 kDa heat shock protein are not 
associated with cardiovascular disease in patients with rheumatoid arthritis. Ann 
Rheum Dis 2006, 65(5):590-594. 
30. Tishler M, Shoenfeld Y: Anti-heat-shock protein antibodies in rheumatic and 
autoimmune diseases. Semin Arthritis Rheum 1996, 26(2):558-563. 
31. Tsoulfa G, Rook GA, Bahr GM, Sattar MA, Behbehani K, Young DB, Mehlert A, 
Van-Embden JD, Hay FC, Isenberg DA et al: Elevated IgG antibody levels to the 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 14 
mycobacterial 65-kDa heat shock protein are characteristic of patients with 
rheumatoid arthritis. Scand J Immunol 1989, 30(5):519-527. 
32. Moreland LW, Koopman WJ: Infection as a cause of arthritis. Curr Opin Rheumatol 
1991, 3(4):639-649. 
33. Pope RM, Wallis RS, Sailer D, Buchanan TM, Pahlavani MA: T cell activation by 
mycobacterial antigens in inflammatory synovitis. Cell Immunol 1991, 133(1):95-
108. 
34. McLean IL, Archer JR, Cawley MI, Pegley FS, Kidd BL, Thompson PW: Specific 
antibody response to the mycobacterial 65 kDa stress protein in ankylosing 
spondylitis and rheumatoid arthritis. Br J Rheumatol 1990, 29(6):426-429. 
35. van der Linden S, Valkenburg HA, Cats A: Evaluation of diagnostic criteria for 
ankylosing spondylitis. A proposal for modification of the New York criteria. 
Arthritis Rheum 1984, 27(4):361-368. 
36. Pedersen M, Jacobsen S, Garred P, Madsen HO, Klarlund M, Svejgaard A, Pedersen 
BV, Wohlfahrt J, Frisch M: Strong combined gene-environment effects in anti-
cyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case-
control study in Denmark. Arthritis Rheum 2007, 56(5):1446-1453. 
37. Prohaszka Z, Duba J, Horvath L, Csaszar A, Karadi I, Szebeni A, Singh M, Fekete B, 
Romics L, Fust G: Comparative study on antibodies to human and bacterial 60 
kDa heat shock proteins in a large cohort of patients with coronary heart disease 
and healthy subjects. Eur J Clin Invest 2001, 31(4):285-292. 
38. Klareskog L, Ronnelid J, Lundberg K, Padyukov L, Alfredsson L: Immunity to 
citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol 2008, 26:651-
675. 
39. Tilleman K, Van Steendam K, Cantaert T, De Keyser F, Elewaut D, Deforce D: 
Synovial detection and autoantibody reactivity of processed citrullinated 
isoforms of vimentin in inflammatory arthritides. Rheumatology (Oxford) 2008, 
47(5):597-604. 
 
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 15 
Table 1 Description of the AS population 
 
Variable (unit) Median±SD Range 
Age (years) 45.4±11.8 26-75 
Male:female ratio 31:12 . 
Age at diagnosis (years) 32.8±10.5 16-57 
BMI (kg/m
2
) 25.0±3.8 19-33 
Disease duration (years) 13.2±10.6 2-40 
Axial:peripheral ratio 33:10 - 
Psoriasis (n; %) 3 (7) - 
Uveitis (n; %) 12 (28) - 
Inflammatory bowel disease (n; %) 2 (5) - 
ESR (mm/h) 15.5±15.6 2-68 
CRP (mg/l) 9.00±11.5 0.5-56.7 
HLA-B27 positivity (%) 83.7 - 
Current smokers (%) 30.2 - 
Pain on VAS (mm) 51.1±31.9 12-90 
Active disease (BASDAI>40; %) 32.6 - 
BASDAI (mm) 50.4±19.1 19-80 
BASFI  45.4±11.8  
BASMI 45.4±11.8  
Current NSAID therapy (%) 86% - 
Current DMARD therapy (%) 14% - 
Current anti-TNF therapy (%) 65% - 
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Dear Professor Boissier, 
 
We wish to thank You and the Reviewers for commenting our manuscript. 
 
We address all isuees as follows: 
 
 
1. We thank the reviewer for finding our paper interesting. We picked anti-MCV as there 
have been numerous papers on anti-CCP and we did not want to repeat those studies. 
Citrullinated vimentin has been detected by others in arthritis synoviual tissues (see 
Tilleman et al), but anti-CV has not yet been studied. The aim of our study was to find 
NEW biomarkers for AS, and anti-MCV is really novel. We did not test anti-CCP on 
this cohort, so we are unable to present such data. 
2.  We agree that the study design is not perfect. While anti-MCV was assessed by a 
commercial ELISA so we did not have any limitation, anti-hsp65 was tested by a 
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performed already in 2009, while the anti-MCV study was done in 2010. 
3. Now we enclosed two figures that are scatter plots to show oriuginal anti-hsp and anti-
MCV results. Accordingly, we deleted Table 2 and included figure legends for the two 
new figs. 
4. None of the patients were genetically related and none of them had RA or other types 
of arthritis in their family. This information is now included int he methodology 
section. 
5. Peripheral vs axial AS classification was determined during the history  of the disease. 
There was no difference between autoantibody levels in axial vs peripheral AS 
patients. Data on extraarticular manifestations are now listed in Table 1. Three patients 
had psoriasis, 12 had uveitis and 2 had IBD. Although these numbers are relatively 
small, we correlated them with the antibodies and found no correlations. This is now 
mentioned in the Results section.  
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publication. 
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